6 research outputs found
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36-3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11-2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.
Funder: Funder: Calgary Laboratory Services (research support fund) Grant reference number: RS19-612Funder: Funder: National Cancer Institute: National Institutes of Health Grant reference number: R01CA172404BACKGROUND: Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (HGSC) when stratified by a 101-gene mRNA expression prognostic signature. Given the varied patient outcomes, this study aimed to translate prognostic mRNA markers into protein expression assays by immunohistochemistry and validate their survival association in HGSC. METHODS: Two prognostic genes, FOXJ1 and GMNN, were selected based on high-quality antibodies, correlation with protein expression and variation in immunohistochemical scores in a preliminary cohort (nâ=â134 and nâ=â80, respectively). Six thousand four hundred and thirty-four (FOXJ1) and 5470 (GMNN) formalin-fixed, paraffin-embedded ovarian neoplasms (4634 and 4185 HGSC, respectively) represented on tissue microarrays from the Ovarian Tumor Tissue Analysis consortium underwent immunohistochemical staining and scoring, then univariate and multivariate survival analysis. RESULTS: Consistent with mRNA, FOXJ1 protein expression exhibited a linear, increasing association with improved overall survival in HGSC patients. Women with >50% expression had the most favourable outcomes (HRâ=â0.78, 95% CI 0.67-0.91, pâ35% GMNN expression showed a trend for better outcomes, though this was not significant. CONCLUSION: We provide foundational evidence for the prognostic value of FOXJ1 in HGSC, validating the prior mRNA-based prognostic association by immunohistochemistry
Recommended from our members
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36-3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11-2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC
Recommended from our members
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.
Funder: Cancer Council Victoria; Id: http://dx.doi.org/10.13039/501100000951Funder: Queensland Cancer FundFunder: Cancer Council New South Wales; Id: http://dx.doi.org/10.13039/501100001102Funder: Cancer Council South Australia; Id: http://dx.doi.org/10.13039/501100000950Funder: Cancer Foundation of Western AustraliaFunder: Cancer Council Tasmania; Id: http://dx.doi.org/10.13039/501100001169Funder: Peter MacCallum Foundation; Id: http://dx.doi.org/10.13039/501100022084Funder: Ovarian Cancer Australia; Id: http://dx.doi.org/10.13039/100011928Funder: ELAN Funds of the University of ErlangenâNurembergFunder: Breast Cancer Now; Id: http://dx.doi.org/10.13039/100009794Funder: Institute of Cancer ResearchFunder: NHSFunder: Biomedical Research CentreFunder: Fondo Europeo de Desarrollo Regional; Id: http://dx.doi.org/10.13039/501100008530Funder: German Cancer Research Center; Id: http://dx.doi.org/10.13039/100008658Funder: Mayo Foundation; Id: http://dx.doi.org/10.13039/100007048Funder: Minnesota Ovarian Cancer Alliance; Id: http://dx.doi.org/10.13039/100003135Funder: Fred C. and Katherine B. Andersen Foundation; Id: http://dx.doi.org/10.13039/100017909Funder: Pomeranian Medical University; Id: http://dx.doi.org/10.13039/501100008781Funder: UK National Institute for Health ResearchFunder: University of Cambridge; Id: http://dx.doi.org/10.13039/501100000735Funder: Clinical Academic ReserveFunder: Oak Foundation; Id: http://dx.doi.org/10.13039/100001275Funder: National Institute for Health Research; Id: http://dx.doi.org/10.13039/501100000272Funder: University College London Hospitals Biomedical Research CentreFunder: The BC Cancer FoundationFunder: VGH and UBC Hospital Foundation; Id: http://dx.doi.org/10.13039/100014823Funder: Cancer Institute NSW; Id: http://dx.doi.org/10.13039/501100001171Funder: Sydney West Translational Cancer Research Centre; Id: http://dx.doi.org/10.13039/100013121Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36-3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11-2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC
Recommended from our members
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.
Funder: Biomedical Research CentreFunder: European Regional Development FundFunder: Mayo Foundation for Medical Education and ResearchFunder: Pomeranian Medical UniversityFunder: Pomorski Uniwersytet Medyczny W SzczecinieFunder: Cancer Council NSWFunder: Cancer Institute NSWFunder: Deutsches KrebsforschungszentrumFunder: The BC Cancer FoundationFunder: University College London Hospitals Biomedical Research CentreFunder: Breast Cancer NowFunder: Cancer Council TasmaniaFunder: Clinical Academic ReserveFunder: ELAN Funds of the University of Erlangen-NurembergFunder: Fondo Europeo de Desarrollo RegionalFunder: National Institute for Health Research (NIHR)Funder: National Institute for Health and Care ResearchFunder: Ovarian Cancer AustraliaFunder: Queensland Cancer FundFunder: Cancer Council New South WalesFunder: Fred C. and Katherine B. Andersen FoundationFunder: German Cancer Research CenterFunder: Institute of Cancer ResearchFunder: Mayo FoundationFunder: Minnesota Ovarian Cancer AllianceFunder: Peter MacCallum FoundationFunder: University of CambridgeFunder: Cancer Foundation of Western AustraliaFunder: VGH and UBC Hospital FoundationFunder: Cancer Council VictoriaFunder: NHSFunder: UK National Institute for Health ResearchFunder: Cancer Council South AustraliaFunder: Oak FoundationFunder: Sydney West Translational Cancer Research CentreOur objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36-3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11-2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC
Recommended from our members
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous [HGSC], endometrioid [EC] and clear cell carcinomas [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93% (4630/4957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (HR=2.18, 95% CI 1.36-3.47, p=0.0011) as well as with CCC (HR=1.57, 95% CI 1.11-2.22, p=0.012). Abnormal p53 was also associated with shorter overall survival in FIGO stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.CRU